Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells.

Related Articles

Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells.

BMC Cancer. 2016 Dec 16;16(1):949

Authors: Zhang X, Pan C, Zhou L, Cai Z, Zhao S, Yu D

Abstract
BACKGROUND: Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells.
METHODS: Knockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested.
RESULTS: We showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo.
CONCLUSIONS: The results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.

PMID: 27986075 [PubMed - in process]

http://ift.tt/2heKGNg